Cargando…
Corrigendum to “Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models”
Autores principales: | Zhang, Qing, Zhang, Haixu, Ding, Jiage, Liu, Hongyan, Li, Huizhong, Li, Hailong, Lu, Mengmeng, Miao, Yangna, Li, Liantao, Zheng, Junnian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458869/ https://www.ncbi.nlm.nih.gov/pubmed/31032372 http://dx.doi.org/10.1155/2019/2070562 |
Ejemplares similares
-
Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
por: Zhang, Qing, et al.
Publicado: (2018) -
Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
por: Zhang, Qing, et al.
Publicado: (2017) -
EpCAM (CD326) finding its role in cancer
por: Baeuerle, P A, et al.
Publicado: (2007) -
The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015) -
Corrigendum to “Peritumoral EpCAM Is an Independent Prognostic Marker after Curative Resection of HBV-Related Hepatocellular Carcinoma”
por: Dai, Xiao-Meng, et al.
Publicado: (2017)